S, M. D., H, A., M, R., N, M. K., Z, A., H, T. G., . . . R, J. (2025). Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: An updated meta-analysis of randomized controlled trials. BMC nephrology, 27(1), 69. https://doi.org/10.1186/s12882-025-04710-2
Chicago Style (17th ed.) CitationS, Muhammad Daniyal, et al. "Combination Therapy with Mineralocorticoid Receptor Antagonists and SGLT2 Inhibitors Versus SGLT2 Inhibitor Monotherapy in Chronic Kidney Disease: An Updated Meta-analysis of Randomized Controlled Trials." BMC Nephrology 27, no. 1 (2025): 69. https://doi.org/10.1186/s12882-025-04710-2.
MLA (9th ed.) CitationS, Muhammad Daniyal, et al. "Combination Therapy with Mineralocorticoid Receptor Antagonists and SGLT2 Inhibitors Versus SGLT2 Inhibitor Monotherapy in Chronic Kidney Disease: An Updated Meta-analysis of Randomized Controlled Trials." BMC Nephrology, vol. 27, no. 1, 2025, p. 69, https://doi.org/10.1186/s12882-025-04710-2.
